Clinical Importance of FNDC-5 and Selectin-E mRNA Expression Among Type 2 Diabetics with and without Obesity.
FNDC-5
expression
mRNA
obesity
selectin-E
type 2 diabetes mellitus
Journal
Diabetes, metabolic syndrome and obesity : targets and therapy
ISSN: 1178-7007
Titre abrégé: Diabetes Metab Syndr Obes
Pays: New Zealand
ID NLM: 101515585
Informations de publication
Date de publication:
2022
2022
Historique:
received:
04
12
2021
accepted:
10
03
2022
entrez:
11
4
2022
pubmed:
12
4
2022
medline:
12
4
2022
Statut:
epublish
Résumé
Type 2 diabetes mellitus (T2DM) is growing illnesses associated with metabolic dysregulation such as obesity affecting a large population become leading causes of death worldwide. Fibronectin type III domain-containing protein 5 (FNDC-5) and selectin-E were suggested to have effects on metabolism and diabetes, therefore present study aimed to evaluate the clinical importance of FNDC-5 and selectin-E among the T2DM patients with and without obesity. Study included cohort of 200 T2DM patients with and without obesity. We evaluated FNDC-5, selectin-E mRNA expression as well as vitamin-D, and vitamin-B12 levels in among the T2DM patients with and without obesity. Study observed significant difference in biochemical parameters included in study. T2DM patients with obesity had significantly higher fasting blood glucose levels (p<0.0001) and HbA1c (glycated hemoglobin) (p<0.0001) compared to those T2DM patients without obesity. T2DM patients with obesity also had higher systolic blood pressure (p=0.001), LDL (low density lipoprotein) (p=0.02), TG (triglycerides) (p=0.02) and cholesterol (p=0.01) compared to T2DM patients without obesity. The mRNA expression of FNDC-5 (p<0.0001) was lower in T2DM patients with obesity compared to T2DM patients without obesity. It was observed that the T2DM patients with vitamin-D deficiency had significantly lower FNDC-5 mRNA expression (p=0.03) when compared with those with sufficient vitamin-D level. T2DM patients with clinically normal vitamin-B12 level expressed 0.60 fold FNDC-5 mRNA expression while B12 deficient T2DM patients had 0.28 fold FNDC-5 mRNA expression (p=0.005). No as such significant association was was observed with selectin-E. A negative correlation of FNDC-5 mRNA expression with Post prandial glucose (mg/dl) (p=0.04) and TG (mg/dl) (p=0.02) was observed. FNDC-5 down regulation was observed with T2DM with obesity, vitamin-D and vitamin-B12 deficiency suggesting obesity, vitamin-D and vitamin-B12 deficiency could be the factor for FNDC-5 down-regulation leading to worseness or progression of disease. We suggest that FNDC-5 down-regulation could be used as an indicator for T2DM worseness and development of other associated complications.
Sections du résumé
Background
UNASSIGNED
Type 2 diabetes mellitus (T2DM) is growing illnesses associated with metabolic dysregulation such as obesity affecting a large population become leading causes of death worldwide. Fibronectin type III domain-containing protein 5 (FNDC-5) and selectin-E were suggested to have effects on metabolism and diabetes, therefore present study aimed to evaluate the clinical importance of FNDC-5 and selectin-E among the T2DM patients with and without obesity.
Methods
UNASSIGNED
Study included cohort of 200 T2DM patients with and without obesity. We evaluated FNDC-5, selectin-E mRNA expression as well as vitamin-D, and vitamin-B12 levels in among the T2DM patients with and without obesity.
Results
UNASSIGNED
Study observed significant difference in biochemical parameters included in study. T2DM patients with obesity had significantly higher fasting blood glucose levels (p<0.0001) and HbA1c (glycated hemoglobin) (p<0.0001) compared to those T2DM patients without obesity. T2DM patients with obesity also had higher systolic blood pressure (p=0.001), LDL (low density lipoprotein) (p=0.02), TG (triglycerides) (p=0.02) and cholesterol (p=0.01) compared to T2DM patients without obesity. The mRNA expression of FNDC-5 (p<0.0001) was lower in T2DM patients with obesity compared to T2DM patients without obesity. It was observed that the T2DM patients with vitamin-D deficiency had significantly lower FNDC-5 mRNA expression (p=0.03) when compared with those with sufficient vitamin-D level. T2DM patients with clinically normal vitamin-B12 level expressed 0.60 fold FNDC-5 mRNA expression while B12 deficient T2DM patients had 0.28 fold FNDC-5 mRNA expression (p=0.005). No as such significant association was was observed with selectin-E. A negative correlation of FNDC-5 mRNA expression with Post prandial glucose (mg/dl) (p=0.04) and TG (mg/dl) (p=0.02) was observed.
Conclusion
UNASSIGNED
FNDC-5 down regulation was observed with T2DM with obesity, vitamin-D and vitamin-B12 deficiency suggesting obesity, vitamin-D and vitamin-B12 deficiency could be the factor for FNDC-5 down-regulation leading to worseness or progression of disease. We suggest that FNDC-5 down-regulation could be used as an indicator for T2DM worseness and development of other associated complications.
Identifiants
pubmed: 35401010
doi: 10.2147/DMSO.S352483
pii: 352483
pmc: PMC8986209
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1011-1021Informations de copyright
© 2022 Verma et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Am J Physiol Endocrinol Metab. 2003 Jan;284(1):E1-6
pubmed: 12388172
Cardiovasc Res. 2015 Aug 1;107(3):331-9
pubmed: 25994174
Circ Heart Fail. 2012 Nov;5(6):812-8
pubmed: 23001918
J Biol Chem. 2011 Jul 22;286(29):25564-73
pubmed: 21659524
Nat Rev Endocrinol. 2017 Jun;13(6):324-337
pubmed: 28211512
Blood. 2010 Jul 22;116(3):485-94
pubmed: 20299514
J Clin Endocrinol Metab. 2013 Apr;98(4):E769-78
pubmed: 23436919
Circ Res. 2016 May 27;118(11):1723-35
pubmed: 27230638
Diabet Med. 2006 May;23(5):469-80
pubmed: 16681555
Endocr Rev. 2001 Aug;22(4):477-501
pubmed: 11493580
BMC Med Genet. 2007 Jun 20;8:35
pubmed: 17578587
Adv Nutr. 2015 Sep 15;6(5):552-63
pubmed: 26374177
Metabolism. 2018 Jun;83:31-41
pubmed: 29374559
Biomolecules. 2021 Feb 20;11(2):
pubmed: 33672565
J Clin Endocrinol Metab. 2013 Dec;98(12):4899-907
pubmed: 24057291
Int J Biol Macromol. 2016 Mar;84:457-63
pubmed: 26712701
Immunity. 2007 Jun;26(6):773-83
pubmed: 17543554
Cardiovasc Diabetol. 2017 Nov 9;16(1):147
pubmed: 29121940
Metabolism. 2014 Apr;63(4):520-31
pubmed: 24439241
J Clin Endocrinol Metab. 2015 May;100(5):2123-30
pubmed: 25781361
Diabetes Metab Res Rev. 2016 Jan;32(1):51-9
pubmed: 25952527
Physiol Rev. 1999 Jan;79(1):181-213
pubmed: 9922371
Curr Diabetes Rev. 2017;13(1):65-80
pubmed: 27515855
J Cachexia Sarcopenia Muscle. 2015 Mar;6(1):62-72
pubmed: 26136413
Rev Diabet Stud. 2013 Summer-Fall;10(2-3):133-56
pubmed: 24380089
Eur J Sport Sci. 2017 Jun;17(5):629-637
pubmed: 28287024
Oncol Rep. 2009 Feb;21(2):357-62
pubmed: 19148508